- Home
- CLSD vs ATRA Comparison
CLSD vs ATRA Comparison
Compare CLSD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- ATRA
- Stock Information
- Founded
- CLSD 2011
- ATRA 2012
- Country
- CLSD United States
- ATRA United States
- Employees
- CLSD N/A
- ATRA N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLSD Health Care
- ATRA Health Care
- Exchange
- CLSD Nasdaq
- ATRA Nasdaq
- Market Cap
- CLSD 68.4M
- ATRA 67.9M
- IPO Year
- CLSD 2016
- ATRA 2014
- Fundamental
- Price
- CLSD $0.42
- ATRA $12.29
- Analyst Decision
- CLSD Hold
- ATRA Strong Buy
- Analyst Count
- CLSD 4
- ATRA 3
- Target Price
- CLSD $4.33
- ATRA $21.00
- AVG Volume (30 Days)
- CLSD 12.9M
- ATRA 65.3K
- Earning Date
- CLSD 08-08-2025
- ATRA 08-11-2025
- Dividend Yield
- CLSD N/A
- ATRA N/A
- EPS Growth
- CLSD N/A
- ATRA N/A
- EPS
- CLSD N/A
- ATRA 0.56
- Revenue
- CLSD $4,166,000.00
- ATRA $188,667,000.00
- Revenue This Year
- CLSD $78.37
- ATRA N/A
- Revenue Next Year
- CLSD $17.79
- ATRA N/A
- P/E Ratio
- CLSD N/A
- ATRA $21.82
- Revenue Growth
- CLSD N/A
- ATRA 202.41
- 52 Week Low
- CLSD $0.29
- ATRA $5.01
- 52 Week High
- CLSD $1.65
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- CLSD 39.95
- ATRA 62.30
- Support Level
- CLSD $0.40
- ATRA $10.32
- Resistance Level
- CLSD $0.47
- ATRA $12.31
- Average True Range (ATR)
- CLSD 0.06
- ATRA 0.90
- MACD
- CLSD 0.01
- ATRA -0.04
- Stochastic Oscillator
- CLSD 26.87
- ATRA 77.93
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).